Pharmacosmos A/S announced that it has entered into an agreement with Pfizer Inc. under which Pfizer would acquire the exclusive commercialization rights to Monofer® in Canada. Monofer®, under development by Pharmacosmos in Canada, is an innovative intravenous iron replacement therapy for the treatment of iron deficiency anaemia (IDA).
The structure of Monofer® is different from other intravenous iron replacement therapies, allowing the possibility to administer high iron doses in less than one hour during one visit to the doctor for the potential benefit and convenience of patients and healthcare professionals.
Terms of the agreement were not disclosed.
Allen Van Der Wee, General Manager, Pfizer Global Established Pharma Business in Canada, said: "We are pleased to work with Pharmacosmos to offer patients with anaemia a potential new treatment option to restore their iron levels."
Pharmacosmos' Chief Executive Officer, Lars Christensen, commented: "We look forward to working with Pfizer in Canada and believe that Monofer® will serve yet unmet clinical needs with a clear potential to improve outcomes and convenience for Canadian patients suffering from Iron Deficiency Anaemia. Our agreement with Pfizer is an important milestone in our ambition to establish Monofer® as a world leading brand for iron deficiency anaemia management."
Fonnesbech & Estrup
Tel: +45 28 74 87 10
Tobias S. Christensen
Vice President, Corporate & Strategy
Tel: +45 40 20 16 62
Switchboard: +45 59 48 59 59
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
Monofer® (iron isomaltoside 1000 for injection) is an iron-carbohydrate complex for intravenous administration. Monofer® is marketed in more than 30 countries worldwide for the treatment of iron deficiency and iron deficiency anaemia. Monofer® is manufactured by Pharmacosmos A/S, Denmark.
Iron deficiency anaemia (IDA) is a debilitating condition that affects almost 1 billion people worldwide. IDA is often associated with many chronic disorders such as renal diseases (including chronic kidney disease), cancers (including chemotherapy-induced anaemia), gynecologic disorders (including abnormal uterine bleeding), and inflammatory bowel disease.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?